Community data
Updated 22 hours ago
Indications
Erdafitinib is a kinase inhibitor. It is used to treat adults with locally advanced or metastatic urothelial carcinoma (mUC) when two things are true. The tumour must have susceptible FGFR3 or FGFR2 genetic alterations. The cancer must also have progressed during or after at least one line of earlier platinum-containing chemotherapy, and this includes progression within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
⚠️ Always consult a registered physician before taking any medicine.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.
Adults: Adults start Erdafitinib at 8 mg once daily, taken by mouth as two 4 mg tablets. After 14 to 21 days the dose may go up to 9 mg once daily (three 3 mg tablets), depending on the serum phosphate (PO4) level and how well the person is tolerating the medicine. Treatment continues until the disease progresses or the toxicity becomes unacceptable.
If a dose of Erdafitinib is missed, it can be taken as soon as possible on the same day. The next day, go back to the usual daily schedule. Don't take extra tablets to make up for the missed dose.